Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year
Executive Summary
Merck's fourth quarter rebound suggests that Wall Street may be looking on the bright side for pharmaceutical stocks at last
You may also be interested in...
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress
Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17